Cellbox Solutions has published a new peer-reviewed research article in collaboration with the Fraunhofer Institute for Cell Therapy and Immunology in Frontiers in Bioengineering and Biotechnology. The study investigates live shipment of ex vivo expanded natural killer (NK) cells as a transport alternative to cryopreservation for cryo-sensitive cell-based therapies.

In the study, allogeneic NK cells derived from healthy donors were transported live using the Cellbox™ Shipper Flight under controlled culture conditions at 37 °C and 5 % CO₂ for approximately 44 hours and compared to cryopreserved cell products. The results demonstrate that live shipment preserves NK cell phenotype, viability, and cytotoxic function, while cryopreservation leads to substantial delayed cell loss and reduced functional recovery.

Figure 3

The publication highlights live shipment as a reliable transport strategy for off-the-shelf NK cell therapies and supports the use of controlled warm-chain logistics for the clinical translation of advanced cell-based therapies.

Read the abstract summarizing live shipment of NK cells.

Read the full peer-reviewed article in Frontiers in Bioengineering and Biotechnology

We thank the Fraunhofer Institute for Cell Therapy and Immunology for the close and constructive scientific collaboration.